85-2071-61 Beclin-1 Activator I, TAT-Beclin-1 (Atg6 Activator I, Beclin1-GAPR-1 Interaction Blocker I, Vps30 Activator I, H2N-YGRKKRRQRRR-GG-TNVFNATFEIWHDGEFGT-CO2H) 10mg 217213
85-2071-61 Beclin-1 Activator I, TAT-Beclin-1 (Atg6 Activator I, Beclin1-GAPR-1 Interaction Blocker I, Vps30 Activator I, H2N-YGRKKRRQRRR-GG-TNVFNATFEIWHDGEFGT-CO2H) 10mg 217213
A cell-permeable autophagy-inducing peptide (Effective conc. 30 to 100uM) that is designed based on the essential HIV-1 virulence factor Nef-binding sequence of atg6/beclin1 and N-terminally fused to the HIV-1 Tat protein transduction domain sequence. Tat-Beclin1 is reported to compete against Beclin1 for binding to its negative regulator GAPR-1/GLIPR2 on the Golgi surface. Shown to effectively induce autophagy-mediated clearance of small (<1uM) CFP-htt103Q aggregates in HeLa cells (20uM/4h/d for 2 d) and inhibit RNA viral replications both in cultures (4h 10uM peptide treatment 4h post CHIKV, SINV, or WNV infection in HeLa cultures; 24h 0.5-5uM peptide pre-treatment before HIV infection in human MDM cultures) in vitro and in mice (15-20mg/kg/day i.p.) in vivo. The in vivo bioavailability of Tat-Beclin1 is limited to the peripheral tissues in mice, while a peptide based on Tat-Beclin1 retro-inverso sequence is demonstrated to effectively target CNS.
Synonyms:Atg6 Activator I, Beclin1-GAPR-1 Interaction Blocker I, Vps30 Activator I, H₂N-YGRKKRRQRRR-GG-TNVFNATFEIWHDGEFGT-CO₂H, Autophagy Inducer IV